Unknown

Dataset Information

0

Antiretroviral drug exposure in urethral and glans surface sampling of the penis.


ABSTRACT:

Background

HIV exposure to penile tissues provides a risk of acquisition among men, yet studies evaluating penile antiretroviral (ARV) drug distribution have been lacking. We measured ARVs on urethral and glans surface swabs collected following a dose of tenofovir alafenamide, emtricitabine, elvitegravir, darunavir and cobicistat.

Methods

Thirty-five HIV-negative male participants provided urethral swabs, glans swabs, rectal swabs, blood and urine up to 96 h following a single dose of tenofovir alafenamide/emtricitabine/elvitegravir/cobicistat and darunavir. ARVs were measured by liquid chromatography-mass spectrometry with a lower limit of detection (LOD) of 1 ng/swab for swabs and 10 ng/mL for plasma and urine. Concentrations are reported as median and range.

Results

Urethral swab emtricitabine and darunavir concentrations peaked at 4 h for emtricitabine (36 ng/swab; 3-307 ng/swab) and 8 h for darunavir (25 ng/swab; 2-52 ng/swab). Glans swab emtricitabine and darunavir concentrations peaked 24 h after dosing (emtricitabine 14 ng/swab, ConclusionsWe document ARV dosing in the urethra and on the glans surface with high drug concentrations noted for emtricitabine and darunavir and lower tenofovir and elvitegravir concentrations. Data suggest a potential protective role of urethral emtricitabine or darunavir against penile HIV acquisition.

SUBMITTER: Haaland RE 

PROVIDER: S-EPMC10134741 | biostudies-literature | 2021 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Antiretroviral drug exposure in urethral and glans surface sampling of the penis.

Haaland Richard E RE   Fountain Jeffrey J   Dinh Chuong C   Lupo L Davis LD   Martin Amy A   Conway-Washington Christopher C   Hall LaShonda L   Kelley Colleen F CF   Garcia-Lerma J Gerardo JG   Heneine Walid W  

The Journal of antimicrobial chemotherapy 20210801 9


<h4>Background</h4>HIV exposure to penile tissues provides a risk of acquisition among men, yet studies evaluating penile antiretroviral (ARV) drug distribution have been lacking. We measured ARVs on urethral and glans surface swabs collected following a dose of tenofovir alafenamide, emtricitabine, elvitegravir, darunavir and cobicistat.<h4>Methods</h4>Thirty-five HIV-negative male participants provided urethral swabs, glans swabs, rectal swabs, blood and urine up to 96 h following a single dos  ...[more]

Similar Datasets

| S-EPMC6815865 | biostudies-literature
| S-EPMC7807328 | biostudies-literature
| S-EPMC3739230 | biostudies-literature
| S-EPMC8267208 | biostudies-literature
| S-EPMC5753559 | biostudies-literature
| S-EPMC6302150 | biostudies-literature
| S-EPMC9018350 | biostudies-literature
| S-EPMC2649883 | biostudies-literature
| S-EPMC5958767 | biostudies-literature
| S-EPMC8039622 | biostudies-literature